Continuum Advisory’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
Other funds holding XBI
JFG
Continuum Advisory's XBI Position: Q2 2026 in Review
Continuum Advisory increased its State Street SPDR S&P Biotech ETF (XBI) stake by 389% in Q2 2026, buying an estimated $1.94M and bringing the position to 18,013 shares worth $2.85M. The position accounts for 0.23% of the portfolio, ranked #97.
Continuum Advisory first reported a position in XBI in Q1 2024 and has held it in 9 quarters since. The position peaked at $3.2M in Q3 2024. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.
- Continuum Advisory held 18,013 shares of State Street SPDR S&P Biotech ETF worth $2.85M as of Q2 2026.
- Continuum Advisory bought 14,330 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $1.94M.
- State Street SPDR S&P Biotech ETF made up 0.23% of Continuum Advisory's portfolio in Q2 2026, its #97 holding.
- Continuum Advisory first reported a position in State Street SPDR S&P Biotech ETF in Q1 2024 and has held it in 9 quarters since.
- Continuum Advisory's State Street SPDR S&P Biotech ETF position peaked at $3.2M in Q3 2024.
- 933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.
Based on Continuum Advisory's 13F filing for Q2 2026, filed 6 Aug 2026.